APPENDICURE

RESEARCH BRIEF  |  MOLECULAR BIOLOGY

First-in-disease m6A epitranscriptomic profiling suggests current classification leaves real biology on the table.

Appendix cancer m6A profiling is the focus of a new study presented at Digestive Disease Week 2026, and the findings suggest that an entire layer of biology has been hiding in plain sight. For decades, the way doctors classify appendix cancer has rested on what a pathologist can see under a microscope. The shape of the cells. The pattern they form. How aggressive they look. From that, patients get a histology (mucinous adenocarcinoma, goblet cell, signet ring, and so on) and a grade (low, moderate, or high). Those categories drive almost every treatment decision: surgery alone or surgery plus HIPEC, chemotherapy choice, surveillance intensity, etc.

It works, except when it doesn’t. Two patients with the same histology and the same grade often have very different outcomes. Some moderately differentiated mucinous adenocarcinomas behave indolently for years; others progress quickly despite identical-looking tissue. Oncologists have known for a long time that the microscope is missing something.

The study, called PACE, is the first published look at the appendix cancer m6A epitranscriptomic landscape. It takes a serious swing at finding what that missing piece is, and the results matter for how clinicians may eventually stratify risk and choose treatment.

This is more technical for my liking, but I tried my best to turn this into plain english. Personally, I had to sit still and read it a few times before it sank in 🙂

Understanding appendix cancer m6A biology

Inside every cell, DNA gets copied into RNA, and RNA gets read by ribosomes to build proteins. That many people remember from biology class (not for me – I wish I had paid more attention in Biology 😉….

What’s less commonly taught is that RNA itself carries chemical tags that act like editorial notes, telling the cell which messages to translate quickly, which to set aside, and which to destroy.

The most common of these tags is called N6-methyladenosine, or m6A. It’s a small chemical modification placed on certain adenosine bases in RNA. A family of enzymes called writers (the most important is METTL3) installs the tags. Erasers remove them. Readers recognize them and decide what happens next. Together, this system tunes how much of each protein gets made and when. Even this version hurts my head….

But I will continue….

When the m6A system breaks down, the consequences ripple through everything: cell growth, immune signaling, response to stress, ability to spread. Researchers have spent the last decade documenting how m6A dysregulation drives a long list of cancers. Appendix cancer, until the PACE study, had been a blank space on that map.

How the PACE study mapped appendix cancer m6A modifications

The PACE team analyzed tumor tissue from 64 patients with appendix cancer alongside 15 normal appendix samples for comparison. They used a technique called MeRIP-seq to map where m6A tags sit across the entire RNA output of each tumor, then paired that with standard RNA sequencing to see how the tags related to gene activity.

The study is a collaboration between Ajay Goel’s lab at City of Hope, Patrick Wagner and Ali Zaidi’s group at Allegheny Health Network, and research teams in China and Japan. The AHN tissue bank, which has been quietly building one of the most useful appendiceal cancer biospecimen collections in the country, made the sample size possible.

What the PACE study found

Three findings stand out.

Appendix cancer tissue carries significantly more m6A modifications than normal appendix tissue. The tags cluster in pathways that control RNA splicing (how a single gene gets edited into different protein versions) and the assembly of membrane-less organelles (cellular structures that organize where RNA molecules congregate). Both are deeply involved in how cells respond to stress and proliferate.

METTL3 is the central driver of appendix cancer m6A dysregulation. When the team mapped the network of dysregulated genes, METTL3 sat at the hub. This matters because METTL3 inhibitors are already in early-phase clinical trials for other cancers. If the finding holds up in larger studies, appendix cancer joins a growing list of malignancies where this class of drug might eventually be relevant. That’s a long path, but it’s a path that didn’t exist before.

The m6A signatures don’t match histology or grade. This is the most important finding for patients trying to make sense of their own case. When the researchers grouped tumors by their m6A patterns, the groups cut across the existing categories. Patients with the same histology landed in different m6A subtypes. Patients with different histologies sometimes landed together. The implication is that current classification, useful as it is, captures only part of the biological reality.

Three different groups, three different methods, one shared conclusion: morphology alone is not enough.

What the appendix cancer m6A findings do not yet show

A few honest caveats matter here.

PACE is a discovery study. The authors describe their work as a framework for an appendix cancer m6A-based risk model, not a validated tool. The abstract does not report survival outcomes, does not show that the m6A subtypes predict response to specific treatments, and does not validate the findings in an independent patient cohort. All of that work has to come next.

The abstract also does not break down which appendiceal histologies were included in the 64-tumor cohort. Appendix cancer is not one disease. LAMN, HAMN, mucinous adenocarcinoma, goblet cell adenocarcinoma, and undifferentiated carcinomas have meaningfully different biology. If the 64 tumors skew heavily toward one subtype, the findings may not apply equally across the others. The full publication should clarify this.

And while METTL3 inhibitors exist, none has been tested in appendix cancer m6A-defined subtypes. The journey from “this enzyme is central in this pathway” to “this drug helps patients with this disease” is a long one and is not guaranteed.

Why the appendix cancer m6A research still matters

Even with those caveats, PACE represents a real shift. It is the first study to look at appendix cancer through the lens of RNA modification biology, and the answers it produced were not trivial. The appendix cancer m6A landscape is genuinely abnormal, the dysregulation has a clear central driver, and the resulting biological subtypes do not map onto the categories clinicians currently use.

PACE also joins a small but growing set of studies pointing in the same direction from different angles. The Zheng and Pywell NGS work showed actionable mutation patterns that vary across histologies. The Mini-Galaxy systems biology framework proposed integrating multiple molecular data types. Now PACE adds a layer that none of those captured. Three different groups, three different methods, one shared conclusion: morphology alone is not enough.

For patients, the practical takeaway is not that anything changes tomorrow. Appendix cancer m6A subtyping is not available clinically. No treatment decision should hinge on it today. But the direction of travel is becoming clear. Within the next five to ten years, molecular profiling of appendix cancer will likely become a real part of how risk is assessed and treatment is chosen. Studies like PACE are how that future gets built.

The harder, slower work now is validation: larger cohorts, longer follow-up, prospective studies that test whether appendix cancer m6A subtypes actually predict outcomes and treatment response. Appendicure will be tracking that work as it develops.

Keep Reading: Several Appendix Cancer Research Updates Today: LAMN, HIPEC, Immunotherapy, Goblet Cell Tumors, and PMP Risk Explained

PACE Study: Kong X, Yang Y, Sherry C, et al. Decoding the m6A Epitranscriptomic Landscape for Molecular Risk Stratification of Appendiceal Cancer, The PACE Study. Gastroenterology. 2026;170(6):S-247 to S-248. Presented at Digestive Disease Week 2026.

© Appendicure. Appendicure is a 501(c)(3) nonprofit dedicated to appendiceal cancer patient education and advocacy.